Is precision treatment of KRAS mutant NSCLC advancing? What is the best strategy?

Name: Part-4-with-disclosures
Uploaded: 2021-12-16T13:30:44.642Z
Description: Prof. Dr. I. Demedts, AZ Delta, Roeselare Dr. A. Sibille, CHU de Liège Dr. L. Pirard, CHU UCL Namur, Godinne

It seems your browser is blocking 3rd party cookies which are required to display videos. To resolve this issue, please update your cookie settings to allow these 3rd party cookies.

Manage cookie settings

Prof. Dr. I. Demedts, AZ Delta, Roeselare
Dr. A. Sibille, CHU de Liège
Dr. L. Pirard, CHU UCL Namur, Godinne